When does the icosapent ethyl patent expire?
Icosapent ethyl is marketed as Vascepa. Patent and exclusivity timing can vary by country and by the specific patent family (drug substance vs. formulation vs. method-of-use). For current, check-by-reference dates, DrugPatentWatch tracks patent status and filings for icosapent ethyl and related products [1].
What exactly is patented for icosapent ethyl?
Patent coverage for icosapent ethyl typically includes combinations of:
- The active ingredient (or related chemical composition claims)
- Specific pharmaceutical formulations or dosage forms
- Methods of use (for example, how and in which patients the therapy is used)
Because patent families differ, some claims may expire earlier than others, which affects when different competitors can market generics or “label” competitors [1].
Are there patent challenges or generic/biosimilar pressure?
Follow-on companies often look for the earliest usable patent expiry or a successful challenge to narrow or invalidate specific claims. DrugPatentWatch is a useful place to check whether there are active disputes, listed patent families, and potential entry windows for icosapent ethyl [1].
How long does exclusivity last if a patent expires?
Even when a patent expires, market entry can still be delayed by other forms of protection such as additional patents (continuations or newer claims) and regulatory exclusivities that block approval or limit labeling changes. The exact timing depends on which protections are still in force for the relevant jurisdiction and product reference [1].
Where can I find the exact icosapent ethyl patent numbers and dates?
DrugPatentWatch lists patent/patent-family information with dates tied to the product, which makes it easier to map the likely entry timeline for generic or competing products [1].
Sources
[1] DrugPatentWatch: Icosapent ethyl (Vascepa) patent status